Clinical summaries, treatment guides, and evidence breakdowns — written for optometrists managing pediatric myopia.
The eye continues to grow during childhood — that's the real driver. What causes it, how fast is too fast, and when to act.
MiSight®, Stellest®, ortho-K, atropine — a head-to-head efficacy comparison with real trial numbers to help you choose.
The IMI 2025 consensus: earlier is better, especially under 10. The clinical triggers, the cost of waiting, and the questions to ask your OD.
How digital tools are changing myopia management workflows — what to look for, and how MyopiaTracker fits into clinical practice.
Almost never — but progression absolutely can be slowed. Evidence-based breakdown of what actually works, and why eye exercises don't.
Most people with myopia don't go blind — but risk rises with axial length. Clear breakdown of real complication risks by AL and diopter.
Normal vs dangerous progression rates by age — in axial length and diopters. Is going from −2 to −5 in two years actually dangerous?
Genetics, outdoor time, and near work — the three-way interaction driving the global myopia epidemic, and what parents can do.
Screen time is associated with myopia — but probably not for the reason you think. The outdoor light factor explains most of the risk.
Wearing glasses doesn't make myopia worse. Not wearing them doesn't make it better. Standard glasses don't affect progression at all.
Eye exercises improve eye strain but cannot change axial length. No RCT shows they slow myopia. Here's the honest, evidence-based answer.
Typically stabilises in the late teens to early 20s — but earlier onset means later stabilisation and higher final prescription.
Stellest 67%, MiSight 55%, ortho-K 50%, atropine 30–58% — every evidence-based treatment with real RCT numbers, in one place.
LASIK corrects vision but doesn't reduce axial length or structural risk. What it does and doesn't do — and who qualifies.